Empowering the body’s natural defenses against life-threatening cancers.

T cell Antigen Coupler (TAC) Platform

Leveraging a T cell’s own recognition, activation and signaling properties.

Our proprietary TAC technology utilizes a novel mechanism of action (MoA) with the potential to enhance the immune response of millions of patients with difficult-to-treat tumors.

Conquering new frontiers in cell therapy.

Co-opting Natural
T Cell Biology

TAC enables T cells to locate and destroy tumor cells through natural activation and maximal, controlled anti-tumor responses.

Broad Applicability
in Cancers

By enabling T cells to target cancer cells using different antigens, TAC may be applied across a wide range of liquid and solid tumors.

Innovative Capabilities in
T cell Manufacturing

We leverage the most advanced manufacturing technologies for optimum product quality.

Co-opting Natural
T Cell Biology

TAC enables T cells to locate and destroy tumor cells through natural activation and maximal, controlled anti-tumor responses.

Broad Applicability
in Cancers

By enabling T cells to target cancer cells using different antigens, TAC may be applied across a wide range of liquid and solid tumors.

Innovative Capabilities in
T cell Manufacturing

We leverage the most advanced manufacturing technologies for optimum product quality.

Pipeline & Programs

Building a robust pipeline of TAC-T cell therapies.

We are developing multiple TAC-based therapeutic candidates using both autologous and allogeneic manufacturing approaches. All programs leveraging our TAC technology have the potential for broad applicability across cancers with a high unmet need.

Recent News

November 13, 2021

Triumvira Announces Data from Gastric Cancer Preclinical Stu…

November 13, 2021

Development of Claudin 18.2-TAC T Cells for the Treatment of…

October 28, 2021

Triumvira Appoints Oncology Industry Veteran Deyaa Adib, M.D…

November 13, 2021

Triumvira Announces Data from Gastric Cancer Preclinical Stu…

November 13, 2021

Development of Claudin 18.2-TAC T Cells for the Treatment of…

October 28, 2021

Triumvira Appoints Oncology Industry Veteran Deyaa Adib, M.D…

Interested in learning more?